Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders' Meeting


EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders' Meeting

15.12.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders' Meeting

Schlieren (Zurich), Switzerland, December 15, 2015 - Cytos Biotechnology Ltd
("Cytos" or "the Company"), announced today that an Extraordinary Shareholders'
Meeting will take place on Wednesday, January 6, 2016 at 10.30 a.m. at Cytos'
offices in Schlieren/Zurich (Switzerland).

At this meeting, shareholders will be invited to vote on resolutions related to
the transaction with Kuros Biosurgery Holding AG (acquisition of this company by
means of share exchange). Resolutions include an increase of the share capital,
amendment of the conditional and authorized capital and elections to the Board
of Directors.

The formal invitation to the meeting will be sent out within the next few days
and can also be downloaded on the following website:

http://www.cytos.com/uploads/2016/Cytos_invitation_EGM_Jan6_english.pdf

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the SIX
Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com

 

End of ad hoc announcement

+++++
Additional features:

Document:http://n.equitystory.com/c/fncls.ssp?u=PDMWHIYFRK
Document title: Cytos_EGM_151215

--------------------------------------------------------------------------------
15.12.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  Cytos Biotechnology AG

          Wagistr. 25

          8952  Schlieren

          Switzerland

Phone:    +41 44 733 4747

Fax:      +41 44 733 4740

E-mail:info@cytos.com

Internet: www.cytos.com

ISIN:     CH0011025217, CH0029060735

Valor:    -

Listed:   Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market
in Frankfurt ; SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
423509  15.12.2015 
 



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: